Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study
To determine the change in established biomarkers of cardiovascular (CV) risk, namely, total cholesterol/high-density lipoprotein cholesterol ratio (TC/HDL-C), N-terminal pro-brain natriuretic peptide (NT-proBNP) and insulin resistance (IR) in patients with early RA treated with two different treat-...
Gespeichert in:
Veröffentlicht in: | Rheumatology (Oxford, England) England), 2016-12, Vol.55 (12), p.2181-2190 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2190 |
---|---|
container_issue | 12 |
container_start_page | 2181 |
container_title | Rheumatology (Oxford, England) |
container_volume | 55 |
creator | Bissell, Lesley-Anne Hensor, Elizabeth M A Kozera, Lukasz Mackie, Sarah L Burska, Agata N Nam, Jacqueline L Keen, Helen Villeneuve, Edith Donica, Helena Buch, Maya H Conaghan, Philip G Andrews, Jacqueline Emery, Paul Morgan, Ann W |
description | To determine the change in established biomarkers of cardiovascular (CV) risk, namely, total cholesterol/high-density lipoprotein cholesterol ratio (TC/HDL-C), N-terminal pro-brain natriuretic peptide (NT-proBNP) and insulin resistance (IR) in patients with early RA treated with two different treat-to-target strategies.
Fasting glucose, lipids, insulin and NT-proBNP were measured at baseline, weeks 26 and 78 in 79 DMARD-naïve RA patients, free of CV disease, as part of a double-blind randomized controlled trial of MTX with either infliximab (IFX) or methylprednisolone as induction therapy. Homeostasis model assessment-estimated IR (HOMA-IR) (glucose*insulin/405) was used to measure IR. Multiple imputation was employed, and linear regression analyses were adjusted for baseline values.
Changes in DAS44-CRP did not differ between the treatment arms at weeks 26 and 78. Mean TC/HDL-C, HOMA-IR and NT-proBNP improved in both groups at weeks 26 and 78, although change in NT-proBNP was not statistically significant at week 78. Changes in TC/HDL-C and NT-proBNP were similar between treatment arms, but HOMA-IR values in the IFX + MTX arm were 42% lower than those treated with MTX + methylprednisolone at week 78 (P = 0.003); the difference remained significant after adjustment for baseline BMI, ACPA positivity, smoking status and intramuscular glucocorticoid use (P = 0.007).
When implementing a treat-to-target approach, treatment of early RA was associated with improvement in TC/HDL-C, HOMA-IR and NT-proBNP, and a greater long-term improvement in HOMA-IR was seen in those treated with IFX.
EU Clinical Trials Register, http://www.clinicaltrialsregister.eu, Eudract-2005-005013-37; ISRTCNregisrty, http://www.isrctn.com, ISRCTN48638981. |
doi_str_mv | 10.1093/rheumatology/kew306 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_rheumatology_kew306</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>27638812</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-db658fc3a5ec9fc72e1f885e8290e08d69dd060ae9d20519ebb930d52b863f133</originalsourceid><addsrcrecordid>eNpNkNtKAzEQhoMotlafQJC8wNocutvsZalVCwVv9HrJbibd6B5Kkm27r-RTmlpbhIEZmP-fw4fQPSWPlKR8bEvoaunbql334y_YcZJcoCGdJCwinLPLc80mA3Tj3CchJKZcXKMBmyZcCMqG6HtZb2y7hRoaj00TwnVVyBaccV42BWDj8NqC9GDxroSDRFdmb2qZH1pSKVDYt7gGX7bewj4oseqsadZB6qFxZgvYHyb8Lmk1BmmrHp_uNwpL60trvHFR2NtV3mFt2xr7EvDyaTHDzneqv0VXWlYO7v7yCH08L97nr9Hq7WU5n62iYkITH6k8iYUuuIyhSHUxZUC1EDEIlhIgQiWpUiQhElLFAo8U8jzlRMUsFwnXlPMR4se5hW2ds6CzjQ3f2j6jJDuQz_6Tz47kg-vh6Np0eQ3q7Dmh5j_DQ4pW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Bissell, Lesley-Anne ; Hensor, Elizabeth M A ; Kozera, Lukasz ; Mackie, Sarah L ; Burska, Agata N ; Nam, Jacqueline L ; Keen, Helen ; Villeneuve, Edith ; Donica, Helena ; Buch, Maya H ; Conaghan, Philip G ; Andrews, Jacqueline ; Emery, Paul ; Morgan, Ann W</creator><creatorcontrib>Bissell, Lesley-Anne ; Hensor, Elizabeth M A ; Kozera, Lukasz ; Mackie, Sarah L ; Burska, Agata N ; Nam, Jacqueline L ; Keen, Helen ; Villeneuve, Edith ; Donica, Helena ; Buch, Maya H ; Conaghan, Philip G ; Andrews, Jacqueline ; Emery, Paul ; Morgan, Ann W</creatorcontrib><description>To determine the change in established biomarkers of cardiovascular (CV) risk, namely, total cholesterol/high-density lipoprotein cholesterol ratio (TC/HDL-C), N-terminal pro-brain natriuretic peptide (NT-proBNP) and insulin resistance (IR) in patients with early RA treated with two different treat-to-target strategies.
Fasting glucose, lipids, insulin and NT-proBNP were measured at baseline, weeks 26 and 78 in 79 DMARD-naïve RA patients, free of CV disease, as part of a double-blind randomized controlled trial of MTX with either infliximab (IFX) or methylprednisolone as induction therapy. Homeostasis model assessment-estimated IR (HOMA-IR) (glucose*insulin/405) was used to measure IR. Multiple imputation was employed, and linear regression analyses were adjusted for baseline values.
Changes in DAS44-CRP did not differ between the treatment arms at weeks 26 and 78. Mean TC/HDL-C, HOMA-IR and NT-proBNP improved in both groups at weeks 26 and 78, although change in NT-proBNP was not statistically significant at week 78. Changes in TC/HDL-C and NT-proBNP were similar between treatment arms, but HOMA-IR values in the IFX + MTX arm were 42% lower than those treated with MTX + methylprednisolone at week 78 (P = 0.003); the difference remained significant after adjustment for baseline BMI, ACPA positivity, smoking status and intramuscular glucocorticoid use (P = 0.007).
When implementing a treat-to-target approach, treatment of early RA was associated with improvement in TC/HDL-C, HOMA-IR and NT-proBNP, and a greater long-term improvement in HOMA-IR was seen in those treated with IFX.
EU Clinical Trials Register, http://www.clinicaltrialsregister.eu, Eudract-2005-005013-37; ISRTCNregisrty, http://www.isrctn.com, ISRCTN48638981.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/kew306</identifier><identifier>PMID: 27638812</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Aftercare ; Aged ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - drug therapy ; Biomarkers - metabolism ; Blood Glucose - drug effects ; Blood Glucose - metabolism ; Cardiovascular Diseases - diagnosis ; Cardiovascular Diseases - etiology ; Cholesterol, HDL - metabolism ; Diabetes Complications - complications ; Double-Blind Method ; Early Diagnosis ; Female ; Glucocorticoids - therapeutic use ; Humans ; Infliximab - therapeutic use ; Insulin - metabolism ; Insulin Resistance - physiology ; Lipid Metabolism - drug effects ; Male ; Methotrexate - therapeutic use ; Methylprednisolone - therapeutic use ; Middle Aged ; Natriuretic Peptide, Brain - metabolism ; Peptide Fragments - metabolism ; Risk Factors ; Surveys and Questionnaires ; Treatment Outcome ; Young Adult</subject><ispartof>Rheumatology (Oxford, England), 2016-12, Vol.55 (12), p.2181-2190</ispartof><rights>The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-db658fc3a5ec9fc72e1f885e8290e08d69dd060ae9d20519ebb930d52b863f133</citedby><cites>FETCH-LOGICAL-c416t-db658fc3a5ec9fc72e1f885e8290e08d69dd060ae9d20519ebb930d52b863f133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27638812$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bissell, Lesley-Anne</creatorcontrib><creatorcontrib>Hensor, Elizabeth M A</creatorcontrib><creatorcontrib>Kozera, Lukasz</creatorcontrib><creatorcontrib>Mackie, Sarah L</creatorcontrib><creatorcontrib>Burska, Agata N</creatorcontrib><creatorcontrib>Nam, Jacqueline L</creatorcontrib><creatorcontrib>Keen, Helen</creatorcontrib><creatorcontrib>Villeneuve, Edith</creatorcontrib><creatorcontrib>Donica, Helena</creatorcontrib><creatorcontrib>Buch, Maya H</creatorcontrib><creatorcontrib>Conaghan, Philip G</creatorcontrib><creatorcontrib>Andrews, Jacqueline</creatorcontrib><creatorcontrib>Emery, Paul</creatorcontrib><creatorcontrib>Morgan, Ann W</creatorcontrib><title>Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study</title><title>Rheumatology (Oxford, England)</title><addtitle>Rheumatology (Oxford)</addtitle><description>To determine the change in established biomarkers of cardiovascular (CV) risk, namely, total cholesterol/high-density lipoprotein cholesterol ratio (TC/HDL-C), N-terminal pro-brain natriuretic peptide (NT-proBNP) and insulin resistance (IR) in patients with early RA treated with two different treat-to-target strategies.
Fasting glucose, lipids, insulin and NT-proBNP were measured at baseline, weeks 26 and 78 in 79 DMARD-naïve RA patients, free of CV disease, as part of a double-blind randomized controlled trial of MTX with either infliximab (IFX) or methylprednisolone as induction therapy. Homeostasis model assessment-estimated IR (HOMA-IR) (glucose*insulin/405) was used to measure IR. Multiple imputation was employed, and linear regression analyses were adjusted for baseline values.
Changes in DAS44-CRP did not differ between the treatment arms at weeks 26 and 78. Mean TC/HDL-C, HOMA-IR and NT-proBNP improved in both groups at weeks 26 and 78, although change in NT-proBNP was not statistically significant at week 78. Changes in TC/HDL-C and NT-proBNP were similar between treatment arms, but HOMA-IR values in the IFX + MTX arm were 42% lower than those treated with MTX + methylprednisolone at week 78 (P = 0.003); the difference remained significant after adjustment for baseline BMI, ACPA positivity, smoking status and intramuscular glucocorticoid use (P = 0.007).
When implementing a treat-to-target approach, treatment of early RA was associated with improvement in TC/HDL-C, HOMA-IR and NT-proBNP, and a greater long-term improvement in HOMA-IR was seen in those treated with IFX.
EU Clinical Trials Register, http://www.clinicaltrialsregister.eu, Eudract-2005-005013-37; ISRTCNregisrty, http://www.isrctn.com, ISRCTN48638981.</description><subject>Adult</subject><subject>Aftercare</subject><subject>Aged</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Biomarkers - metabolism</subject><subject>Blood Glucose - drug effects</subject><subject>Blood Glucose - metabolism</subject><subject>Cardiovascular Diseases - diagnosis</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Cholesterol, HDL - metabolism</subject><subject>Diabetes Complications - complications</subject><subject>Double-Blind Method</subject><subject>Early Diagnosis</subject><subject>Female</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Infliximab - therapeutic use</subject><subject>Insulin - metabolism</subject><subject>Insulin Resistance - physiology</subject><subject>Lipid Metabolism - drug effects</subject><subject>Male</subject><subject>Methotrexate - therapeutic use</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Middle Aged</subject><subject>Natriuretic Peptide, Brain - metabolism</subject><subject>Peptide Fragments - metabolism</subject><subject>Risk Factors</subject><subject>Surveys and Questionnaires</subject><subject>Treatment Outcome</subject><subject>Young Adult</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkNtKAzEQhoMotlafQJC8wNocutvsZalVCwVv9HrJbibd6B5Kkm27r-RTmlpbhIEZmP-fw4fQPSWPlKR8bEvoaunbql334y_YcZJcoCGdJCwinLPLc80mA3Tj3CchJKZcXKMBmyZcCMqG6HtZb2y7hRoaj00TwnVVyBaccV42BWDj8NqC9GDxroSDRFdmb2qZH1pSKVDYt7gGX7bewj4oseqsadZB6qFxZgvYHyb8Lmk1BmmrHp_uNwpL60trvHFR2NtV3mFt2xr7EvDyaTHDzneqv0VXWlYO7v7yCH08L97nr9Hq7WU5n62iYkITH6k8iYUuuIyhSHUxZUC1EDEIlhIgQiWpUiQhElLFAo8U8jzlRMUsFwnXlPMR4se5hW2ds6CzjQ3f2j6jJDuQz_6Tz47kg-vh6Np0eQ3q7Dmh5j_DQ4pW</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Bissell, Lesley-Anne</creator><creator>Hensor, Elizabeth M A</creator><creator>Kozera, Lukasz</creator><creator>Mackie, Sarah L</creator><creator>Burska, Agata N</creator><creator>Nam, Jacqueline L</creator><creator>Keen, Helen</creator><creator>Villeneuve, Edith</creator><creator>Donica, Helena</creator><creator>Buch, Maya H</creator><creator>Conaghan, Philip G</creator><creator>Andrews, Jacqueline</creator><creator>Emery, Paul</creator><creator>Morgan, Ann W</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20161201</creationdate><title>Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study</title><author>Bissell, Lesley-Anne ; Hensor, Elizabeth M A ; Kozera, Lukasz ; Mackie, Sarah L ; Burska, Agata N ; Nam, Jacqueline L ; Keen, Helen ; Villeneuve, Edith ; Donica, Helena ; Buch, Maya H ; Conaghan, Philip G ; Andrews, Jacqueline ; Emery, Paul ; Morgan, Ann W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-db658fc3a5ec9fc72e1f885e8290e08d69dd060ae9d20519ebb930d52b863f133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aftercare</topic><topic>Aged</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Biomarkers - metabolism</topic><topic>Blood Glucose - drug effects</topic><topic>Blood Glucose - metabolism</topic><topic>Cardiovascular Diseases - diagnosis</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Cholesterol, HDL - metabolism</topic><topic>Diabetes Complications - complications</topic><topic>Double-Blind Method</topic><topic>Early Diagnosis</topic><topic>Female</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Infliximab - therapeutic use</topic><topic>Insulin - metabolism</topic><topic>Insulin Resistance - physiology</topic><topic>Lipid Metabolism - drug effects</topic><topic>Male</topic><topic>Methotrexate - therapeutic use</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Middle Aged</topic><topic>Natriuretic Peptide, Brain - metabolism</topic><topic>Peptide Fragments - metabolism</topic><topic>Risk Factors</topic><topic>Surveys and Questionnaires</topic><topic>Treatment Outcome</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bissell, Lesley-Anne</creatorcontrib><creatorcontrib>Hensor, Elizabeth M A</creatorcontrib><creatorcontrib>Kozera, Lukasz</creatorcontrib><creatorcontrib>Mackie, Sarah L</creatorcontrib><creatorcontrib>Burska, Agata N</creatorcontrib><creatorcontrib>Nam, Jacqueline L</creatorcontrib><creatorcontrib>Keen, Helen</creatorcontrib><creatorcontrib>Villeneuve, Edith</creatorcontrib><creatorcontrib>Donica, Helena</creatorcontrib><creatorcontrib>Buch, Maya H</creatorcontrib><creatorcontrib>Conaghan, Philip G</creatorcontrib><creatorcontrib>Andrews, Jacqueline</creatorcontrib><creatorcontrib>Emery, Paul</creatorcontrib><creatorcontrib>Morgan, Ann W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bissell, Lesley-Anne</au><au>Hensor, Elizabeth M A</au><au>Kozera, Lukasz</au><au>Mackie, Sarah L</au><au>Burska, Agata N</au><au>Nam, Jacqueline L</au><au>Keen, Helen</au><au>Villeneuve, Edith</au><au>Donica, Helena</au><au>Buch, Maya H</au><au>Conaghan, Philip G</au><au>Andrews, Jacqueline</au><au>Emery, Paul</au><au>Morgan, Ann W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><addtitle>Rheumatology (Oxford)</addtitle><date>2016-12-01</date><risdate>2016</risdate><volume>55</volume><issue>12</issue><spage>2181</spage><epage>2190</epage><pages>2181-2190</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>To determine the change in established biomarkers of cardiovascular (CV) risk, namely, total cholesterol/high-density lipoprotein cholesterol ratio (TC/HDL-C), N-terminal pro-brain natriuretic peptide (NT-proBNP) and insulin resistance (IR) in patients with early RA treated with two different treat-to-target strategies.
Fasting glucose, lipids, insulin and NT-proBNP were measured at baseline, weeks 26 and 78 in 79 DMARD-naïve RA patients, free of CV disease, as part of a double-blind randomized controlled trial of MTX with either infliximab (IFX) or methylprednisolone as induction therapy. Homeostasis model assessment-estimated IR (HOMA-IR) (glucose*insulin/405) was used to measure IR. Multiple imputation was employed, and linear regression analyses were adjusted for baseline values.
Changes in DAS44-CRP did not differ between the treatment arms at weeks 26 and 78. Mean TC/HDL-C, HOMA-IR and NT-proBNP improved in both groups at weeks 26 and 78, although change in NT-proBNP was not statistically significant at week 78. Changes in TC/HDL-C and NT-proBNP were similar between treatment arms, but HOMA-IR values in the IFX + MTX arm were 42% lower than those treated with MTX + methylprednisolone at week 78 (P = 0.003); the difference remained significant after adjustment for baseline BMI, ACPA positivity, smoking status and intramuscular glucocorticoid use (P = 0.007).
When implementing a treat-to-target approach, treatment of early RA was associated with improvement in TC/HDL-C, HOMA-IR and NT-proBNP, and a greater long-term improvement in HOMA-IR was seen in those treated with IFX.
EU Clinical Trials Register, http://www.clinicaltrialsregister.eu, Eudract-2005-005013-37; ISRTCNregisrty, http://www.isrctn.com, ISRCTN48638981.</abstract><cop>England</cop><pmid>27638812</pmid><doi>10.1093/rheumatology/kew306</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1462-0324 |
ispartof | Rheumatology (Oxford, England), 2016-12, Vol.55 (12), p.2181-2190 |
issn | 1462-0324 1462-0332 |
language | eng |
recordid | cdi_crossref_primary_10_1093_rheumatology_kew306 |
source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Alma/SFX Local Collection |
subjects | Adult Aftercare Aged Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Biomarkers - metabolism Blood Glucose - drug effects Blood Glucose - metabolism Cardiovascular Diseases - diagnosis Cardiovascular Diseases - etiology Cholesterol, HDL - metabolism Diabetes Complications - complications Double-Blind Method Early Diagnosis Female Glucocorticoids - therapeutic use Humans Infliximab - therapeutic use Insulin - metabolism Insulin Resistance - physiology Lipid Metabolism - drug effects Male Methotrexate - therapeutic use Methylprednisolone - therapeutic use Middle Aged Natriuretic Peptide, Brain - metabolism Peptide Fragments - metabolism Risk Factors Surveys and Questionnaires Treatment Outcome Young Adult |
title | Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T06%3A59%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improvement%20in%20insulin%20resistance%20is%20greater%20when%20infliximab%20is%20added%20to%20methotrexate%20during%20intensive%20treatment%20of%20early%20rheumatoid%20arthritis-results%20from%20the%20IDEA%20study&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=Bissell,%20Lesley-Anne&rft.date=2016-12-01&rft.volume=55&rft.issue=12&rft.spage=2181&rft.epage=2190&rft.pages=2181-2190&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/kew306&rft_dat=%3Cpubmed_cross%3E27638812%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27638812&rfr_iscdi=true |